Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole by Patel, Chirag G et al.
© 2011 Boulton et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Pharmacology: Advances and Applications 2011:2 13–25
Clinical Pharmacology: Advances and Applications Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
13
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CPAA.S15227
Two-way pharmacokinetic interaction 
studies between saxagliptin and cytochrome 
P450 substrates or inhibitors: simvastatin, 
diltiazem extended-release, and ketoconazole
Chirag g Patel 
Li Li 
suzette girgis 
David M Kornhauser 
ernest U Frevert 
David W Boulton
Bristol-Myers squibb, Princeton,  
nJ, UsA
Correspondence: David   W Boulton 
Bristol-Myers squibb, route 206 and 
Province Line road,  
Princeton, nJ 08543, UsA 
Tel +1 609 252 3395 
Fax +1 609 252 7822 
email david.boulton@bms.com
Background: Many medicines, including several cholesterol-lowering agents (eg,   lovastatin, 
simvastatin), antihypertensives (eg, diltiazem, nifedipine, verapamil), and antifungals 
(eg, ketoconazole) are metabolized by and/or inhibit the cytochrome P450 (CYP) 3A4   metabolic 
pathway. These types of medicines are commonly coprescribed to treat comorbidities in patients 
with type 2 diabetes mellitus (T2DM) and the potential for drug-drug interactions of these 
medicines with new medicines for T2DM must be carefully evaluated.
Objective: To investigate the effects of CYP3A4 substrates or inhibitors, simvastatin (substrate), 
diltiazem (moderate inhibitor), and ketoconazole (strong inhibitor) on the pharmacokinetics 
and safety of saxagliptin, a CYP3A4/5 substrate; and the effects of saxagliptin on these agents 
in three separate studies.
Methods: Healthy subjects were administered saxagliptin 10 mg or 100 mg. Simvastatin, 
diltiazem extended-release, and ketoconazole doses of 40 mg once daily, 360 mg once daily, 
and 200 mg twice daily, respectively, were used to determine two-way pharmacokinetic 
interactions.
Results: Coadministration of simvastatin, diltiazem extended-release, or ketoconazole increased 
mean area under the concentration-time curve values (AUC) of saxagliptin by 12%, 109%, and 
145%, respectively, versus saxagliptin alone. Mean exposure (AUC) of the CYP3A4-generated 
active metabolite of saxagliptin, 5-hydroxy saxagliptin, decreased with coadministration of 
simvastatin, diltiazem, and ketoconazole by 2%, 34%, and 88%, respectively. All adverse 
events were considered mild or moderate in all three studies; there were no serious adverse 
events or deaths.
Conclusion: Saxagliptin, when coadministered with simvastatin, diltiazem extended-release, 
or ketoconazole, was safe and generally well tolerated in healthy subjects. Clinically meaningful 
interactions of saxagliptin with simvastatin and diltiazem extended-release are not expected. 
The dose of saxagliptin does not need to be adjusted when coadministered with a substrate or 
moderate inhibitor of CYP3A4. A limitation to the lowest clinical dose of saxagliptin (2.5 mg) 
is proposed when it is coadministered with a potent CYP3A4 inhibitor such as ketoconazole.
Keywords: cytochrome P450 3A4/5, diltiazem extended-release, ketoconazole, pharmacokinetics, 
simvastatin, type 2 diabetes mellitus
Introduction
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved as an adjunct 
to diet and exercise to improve glycemic control in patients with type 2 diabetes 
mellitus (T2DM), both as monotherapy and in combination therapy.1 DPP-4 is Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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a proteolytic enzyme that cleaves glucagon-like-peptide-1 
(GLP-1), an incretin hormone secreted from the gastro-
intestinal tract in response to food intake. Due to this 
inactivation by DPP-4, GLP-1 has a very short plasma 
half-life (less than two minutes).2 By inhibiting DPP-4, 
saxagliptin slows the inactivation of GLP-1 and improves 
postprandial insulin secretion in a glucose-dependent manner. 
  Saxagliptin is metabolized by cytochrome P450 (CYP) 3A4/5 
enzymes to the   pharmacologically active major   metabolite, 
5-  hydroxy saxagliptin, which has one-half the DPP-4 
  inhibitive potency of the parent saxagliptin.1 The contribution 
of 5-hydroxy saxagliptin to the overall efficacy of saxagliptin 
therapy is not known. In vitro data suggest that saxagliptin 
is a weak substrate for the efflux transporter, P-glycoprotein. 
Both saxagliptin and 5-hydroxy saxagliptin are excreted 
in urine, with renal clearances of approximately 230 and 
120 mL/min, respectively, indicating that saxagliptin is also 
actively renally excreted.1 However, none of the key renal 
transporters, including organic anion transporter (OAT-1, -3), 
organic anion transporter polypeptide (OATP-A, -C, -8), 
organic cation transporter (OCT-1, -2), sodium taurocholate 
cotransporting peptide, and peptide transporters (PepT-1, -2) 
were observed to translocate saxagliptin.
In vitro studies suggest that neither saxagliptin nor 
5-hydroxy saxagliptin inhibits CYP1A2, 2A6, 2B6, 2C9, 
2C19, 2D6, 2E1, or 3A4. Additionally, in vitro studies 
s  uggest saxagliptin and 5-hydroxy saxagliptin do not induce 
CYP1A2, 2B6, 2C9, or 3A4.1 The pharmacokinetics of 
saxagliptin have been observed to be linear over a wide 
range of doses (2.5 to 400 mg administered once daily).1 
During the clinical pharmacology program, saxagliptin has 
been shown to be safe and well tolerated, with no cases of 
confirmed hypoglycemia reported for saxagliptin doses up 
to 400 mg once daily in healthy subjects.
Three separate clinical pharmacology studies have assessed 
the pharmacokinetic effects and safety of saxagliptin in healthy 
adult subjects when combined with each of three   commonly 
used agents, ie, a CYP3A4 substrate (simvastatin), a m  oderate 
inhibitor (diltiazem extended-release), and a strong i  nhibitor 
(ketoconazole). The doses of saxagliptin used in these 
drug-drug interaction studies fall within the l  inear range of 
saxagliptin pharmacokinetics. The usual clinical doses of 
saxagliptin in the US are 2.5 or 5 mg once daily.1
Methods
subjects
Written informed consent was obtained from healthy subjects 
(body mass index [BMI] 18–35 kg/m2 [simvastatin study], 
BMI 18–32 kg/m2 [diltiazem extended-release study], BMI 
18–30 kg/m2 [ketoconazole study], and age 18−45 years). 
Before entering each study, the subjects were ascertained to 
be in good health based on medical history, physical exami-
nation, 12-lead electrocardiogram, and clinical laboratory 
determinations.
None of the subjects had any significant acute or chronic 
medical illness; gastrointestinal disease within three months; 
gastrointestinal surgery that might affect study drug absorp-
tion; history of drug or alcohol abuse within six months; 
or use of oral, injectable, or implantable hormonal contra-
ceptive agents within three months of enrollment. None 
of the patients in the simvastatin study had a history of 
rhabdomyolysis. C  urrent or recent history of smoking was 
prohibited. A complete list of inclusion and exclusion criteria 
is provided in the Electronic Supplementary Table 1 in the 
Online Appendix.
All three trial protocols, protocol amendments, and 
informed consents were approved by an institutional review 
board and were carried out in accordance with the   Declaration 
of Helsinki and Good Clinical Practice   guidelines. All patients 
provided written informed consent.
study designs
The three study designs are shown in Figure 1. With the 
exception of ketoconazole, all other treatments were admin-
istered in the morning. Because the interaction assessments 
were within the subject comparisons between the different 
treatments, the time of dose administration during the day 
(whether morning or evening) was considered unlikely to 
affect the outcome of the study. Only ketoconazole, which 
was administered twice daily, has a second dose being 
administered in the evening. All other treatments were 
administered in the morning. Subject demographics and 
baseline   characteristics for each of the three studies are 
listed in Table 1. The doses of saxagliptin used in these 
studies were either 10 or 100 mg, because these studies 
were conducted at various stages of the saxagliptin clinical 
development program and the doses used were the highest 
clinical dose of saxagliptin being used in the long-term 
safety and efficacy studies at that time. A 10 mg (2 × 5 mg 
tablets) dose of saxagliptin (Onglyza®; Bristol-Myers Squibb, 
Princeton, NJ; AstraZeneca, Wilmington, DE, USA), the 
highest dose used in Phase III studies, was used in the sim-
vastatin (Zocor®; Merck & Co Inc, Whitehouse Station, NJ, 
USA) and diltiazem extended-release (Cardizem LA®; Biovail 
Corporation,   Mississauga, ON, Canada) studies; saxagliptin 
100 mg, the highest dose used in the Phase IIb dose-ranging   Clinical Pharmacology: Advances and Applications 2011:2
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Figure 1 Pharmacokinetic drug interaction study with saxagliptin and simvastatin, diltiazem extended-release, or ketoconazole in healthy subjects—study design. 
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study, was used in the ketoconazole study (Nizoral®; Janssen 
P  harmaceutica,   Titusville, NJ, USA). The clinical dosage for 
saxagliptin is 2.5 or 5 mg administered once daily.1
simvastatin study
On day-1, qualified subjects entered the clinical facility and 
were confined for the duration of the study (until day 13). 
Subjects received saxagliptin 10 mg and simvastatin 40 mg 
(Figure 1).
Diltiazem extended-release study
Subjects underwent screening evaluations to determine 
e  ligibility within 21 days prior to study drug   administration. 
On day-1, subjects entered the clinical facility and were 
  confined for the duration of the study (until day 11). 
S  axagliptin 10 mg and diltiazem extended-release 360 mg 
were administered (Figure 1).
Ketoconazole study
Subjects underwent screening evaluations to determine 
e  ligibility within 21 days prior to study drug   administration. 
On day-1, subjects entered the clinical facility and were 
c  onfined for the duration of the study (until day 12). 
S  axagliptin 100 mg and ketoconazole 200 mg twice daily 
were administered (Figure 1).
investigations
Physical examinations, vital sign measurements, 12-lead 
electrocardiograms, and clinical laboratory evaluations were 
performed at selected times throughout the studies; all sub-
jects were closely monitored for adverse events. Liver func-
tion tests were performed to determine if any safety issues 
were present with respect to liver toxicity from k  etoconazole 
dosing. If liver function tests were considered by the inves-
tigator and medical monitor to be elevated, the subject was 
discontinued from the study.
Blood sampling and drug analysis
simvastatin study 
Serial blood samples for pharmacokinetic analysis were 
collected on days 4 and 12 for saxagliptin and 5-hydroxy 
saxagliptin, as well as on days 8 and 12 for simvastatin and 
simvastatin acid at the following times: predose and 0.25, 0.5, 
1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, and 24 hours postdose.
Timed blood samples (6 mL for saxagliptin and 5-  hydroxy 
saxagliptin collectively and 6 mL for simvastatin and Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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Table 1 subject demographics and baseline characteristics of the 
three studies of saxagliptin and simvastatin, diltiazem extended-
release, and ketoconazole
Characteristic Phase I study
Simvastatin 
(n = 24)
Diltiazem 
XR 
(n = 14)
Ketoconazole 
(n = 16)
Age, years
  Mean (sD) 30 (8) 30 (7) 36 (6)
  range 19–44 22–42 22–43
gender, n (%)
  Men 24 (100) 9 (64) 13 (81)
  Women 0 5 (36) 3 (19)
race, n (%)
  White 8 (33) 5 (36) 16 (100)
  Black 13 (54) 6 (43) 0
  Asian 2 (8) 2 (14) 0
  Other 1 (4) 1 (7) 0
ethnicity, n (%)
  not hispanic – 9 (64) –
  hispanic – 5 (36) –
Weight, kg
  Mean (sD) 83.5 (14.2) 75.1 (9.9) 74.7 (13.1)
  range 59.4–114.1 55.2–91.8 50.1–95.0
height, cm
  Mean (sD) 178.0 (7.7) 170.2 (8.1) 168.8 (8.7)
  range 164.0–190.3 154.1–182.0 154.0–179.0
BMi, kg/m2
  Mean (sD) 26.3 (3.8) 25.9 (2.6) 26.0 (2.6)
  range 18.1–33.2 21.3–30.7 21.1–30.3
Abbreviations:  BMi,  body  mass  index;  sD,  standard  deviation;  Xr,  extended-
release.
s  imvastatin acid) were collected from an indwelling catheter 
or by direct venipuncture and drawn into the anticoagulant 
(K2EDTA for saxagliptin and 5-hydroxy   saxagliptin and 
sodium heparin for simvastatin and   simvastatin acid) contain-
ing tubes. Plasma was separated within 15 minutes.
Plasma concentrations of saxagliptin, 5-hydroxy 
saxagliptin, simvastatin, and simvastatin acid were quan-
tified by the liquid chromatography/mass spectrometry 
(LC/MS/MS) method. The lower limit of quantitation for 
saxagliptin, 5-hydroxy saxagliptin, simvastatin, and sim-
vastatin acid was established at 1.00 ng/mL, 2.00 ng/mL, 
0.15 ng/mL, and 0.05 ng/mL, respectively. The standard curve 
ranges for saxagliptin, 5-hydroxy saxagliptin, simvastatin, 
and simvastatin acid were 1–100 ng/mL, 2–200 ng/mL, 
0.15–60.0 ng/mL, and 0.05–20.0 ng/mL, respectively.
Diltiazem extended-release study
Serial blood samples were collected for pharmacokinetic 
analysis of saxagliptin and 5-hydroxy saxagliptin on days 1 
and 9 at the following times: predose and 0.25, 0.5, 1, 1.5, 2, 
2.5, 3, 4, 6, 8, 12, 18, and 24 hours, as well as on day 10 at 36 
and 48 hours postdose. Blood samples for pharmacokinetic 
analysis of diltiazem were collected at the following times: 
on days 6 and 7 at   predose; on days 8 and 9 at predose and 
4, 6, 8, 10, 11, 12, 13, 14, 16, 18, and 20 hours postdose; and 
on day 10 at predose.
Timed blood samples (approximately 2 mL for   saxagliptin 
and 5-hydroxy saxagliptin, and approximately 4 mL for dilti-
azem) were collected from an indwelling catheter or by direct 
venipuncture and drawn into the anticoagulant (K2EDTA for 
saxagliptin and 5-hydroxy saxagliptin and sodium heparin 
for diltiazem) containing tubes. Plasma was separated within 
15 minutes (diltiazem) and 30 minutes (saxagliptin and 
5-hydroxy saxagliptin).
Plasma concentrations of saxagliptin, 5-hydroxy saxaglip-
tin, and diltiazem were quantified by the LC/MS/MS method. 
The lower limit of quantitation for saxagliptin, 5-hydroxy 
saxagliptin, and diltiazem was established at 1.00 ng/mL, 
2.00 ng/mL, and 0.100 ng/mL, respectively. The standard 
curve range for diltiazem was 0.1–200 ng/mL.
Ketoconazole study
After the first dose of saxagliptin on day 1, serial blood sam-
ples were collected for 48 hours after dosing to determine 
the pharmacokinetic profile of saxagliptin and 5-hydroxy 
saxagliptin. On day 3, subjects commenced a 200 mg twice 
daily ketoconazole regimen. Trough blood samples were 
collected before the morning dose on days 6 and 7 to assess 
ketoconazole concentrations. Serial blood samples were 
collected for 12 hours after dosing to determine the pharma-
cokinetic profile of ketoconazole. Subjects received saxa-
gliptin 100 mg (single dose) and ketoconazole 200 mg once 
every 12 hours on day 9. Serial blood samples were collected 
for 72 hours to determine the pharmacokinetic profile of   
5-hydroxy saxagliptin, and ketoconazole (0–12 hours) 
(Supplementary Table 2 in the Online Appendix).
Timed blood samples (2 mL for saxagliptin and 5-  hydroxy 
saxagliptin collectively and 7 mL for   ketoconazole) 
were c  ollected from an indwelling catheter or by direct 
venipuncture and drawn into the anticoagulant (K3EDTA for 
saxagliptin and 5-hydroxy saxagliptin and sodium heparin 
for ketoconazole) containing tubes. Plasma was separated 
within 15 minutes.
Plasma concentrations of saxagliptin, 5-hydroxy   
saxagliptin, and ketoconazole were quantified by the   
LC/MS/MS method. Estimates of within- and between-day 
variation were calculated using one-way analysis of variance 
(ANOVA). The ranges of the standard curves (saxagliptin 
5–1000 ng/mL; 5-hydroxy saxagliptin 10–2000 ng/mL; Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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ketoconazole 0.05–5.00 µg/mL) were used to define the 
quantifiable limits for the study samples.
Pharmacokinetic analysis
Individual plasma saxagliptin, 5-hydroxy saxagliptin, 
s  imvastatin, simvastatin acid, diltiazem, and   ketoconazole 
concentration  versus  time  data  were  analyzed  by 
n  oncompartmental methods using the validated pharma-
cokinetic analysis program, Kinetica (version 4.2 [diltiazem 
extended-release and ketoconazole studies] and version 4.4.1 
[simvastatin study]; Thermo Fisher Scientific Inc., Philadel-
phia, PA). Maximum observed concentration (Cmax) and time 
of maximum observed concentration (Tmax) were recorded 
directly from experimental observations. The area under the 
concentration-time curve during a dosing interval (AUCτ), 
the area under the concentration-time curve from zero to the 
time of last quantifiable concentration (AUC0-t) for saxagliptin 
and 5-hydroxy saxagliptin were calculated by log- and linear-
trapezoidal summations in both the diltiazem extended-
release and ketoconazole studies. Using no weighting factor, 
the slopes of the terminal phases of the plasma saxagliptin 
and 5-hydroxy saxagliptin concentration-time profiles (λ) 
were determined by log-linear regression of at least three data 
points, which yielded a minimum mean square error. The ter-
minal half-life (t½) of saxagliptin and 5-hydroxy saxagliptin 
were calculated as follows: t½ = ln 2/λ. The area under the 
concentration-time curves from zero extrapolated to infinite 
time (AUC∞) for saxagliptin and 5-hydroxy   saxagliptin were 
calculated by log- and linear-trapezoidal summations over 
the sample collection period; the last quantifiable plasma 
concentration was divided by λ, and the product added to 
the total area (in both the diltiazem extended-release and 
ketoconazole studies).
statistical analysis
simvastatin study
Lack of an effect of simvastatin on the pharmacokinetics 
of saxagliptin was to be concluded if the 90% confidence 
intervals (CI) for the day 12 to day 4 ratios of population 
geometric means were contained within 0.80 and 1.25 for 
both Cmax and AUCτ of saxagliptin. If coadministration 
of simvastatin had no effect on the pharmacokinetics of 
saxagliptin, then a sample size of 20 subjects would provide 
at least 99% power with respect to each of Cmax and AUCτ of 
saxagliptin to conclude that simvastatin had no effect on the 
pharmacokinetics of saxagliptin.
Lack of an effect of saxagliptin on the   pharmacokinetics 
of simvastatin was to be concluded if the 90% CI for the 
day 12 to day 8 ratios of population geometric means were 
contained within 0.70 and 1.43 for both Cmax and AUCτ of 
simvastatin. If coadministration of saxagliptin had no effect 
on the pharmacokinetics of simvastatin, then a sample 
size of 20 subjects would provide at least 91% and at least 
96% power with respect to Cmax and AUCτ of simvastatin, 
respectively, to conclude that saxagliptin had no effect on 
the pharmacokinetics of simvastatin. To allow for dropouts, 
24 subjects were to be enrolled.
ANOVA was performed on Cmax and AUCτ of each analyte 
(factors in the ANOVA were subject and study day). A priori, 
the variables Cmax and AUCτ were log-transformed. Point 
estimates and 90% CIs for treatment differences on the log 
scale were exponentiated to obtain point estimates and 90% 
CIs for the ratios of geometric means on the original scale of 
measurement. Lack of an effect of simvastatin on the phar-
macokinetics of saxagliptin was concluded if the 90% CIs 
for the day 12 to day 4 ratios of population geometric means 
were contained within 0.8 and 1.25 for both Cmax and AUCτ 
of saxagliptin. Lack of an effect of saxagliptin on the phar-
macokinetics of simvastatin was concluded if the 90% CIs 
for the day 12 to day 8 ratios of population geometric means 
were contained within 0.70 and 1.43 for both Cmax and AUCτ 
of simvastatin. Summary statistics were tabulated for Cmax, 
AUCτ, and Tmax by each study day for saxagliptin, 5-hydroxy 
saxagliptin, simvastatin, and simvastatin acid. Geometric 
means and coefficients of variation were presented for Cmax 
and AUCτ. Medians and ranges were presented for Tmax.
Diltiazem extended-release study
The sample size for this study was not based on statistical 
power considerations. However, data from 12 subjects would 
provide at least 98% CI that the point estimate for the day 
9 to day 1 ratio of geometric means for Cmax of saxagliptin 
would be within 20% of the true ratio of population geomet-
ric means and would provide at least 99% CI that the point 
estimate for the day 9 to day 1 ratio of geometric means 
for AUC∞ of saxagliptin would be within 20% of the true 
ratio of population geometric means. To allow for dropouts, 
14 subjects were to be enrolled.
ANOVA was performed on Cmax, AUC∞, and AUC0-t of 
saxagliptin and 5-hydroxy saxagliptin, and on Cmax and AUCτ of 
diltiazem extended-release (factors in the ANOVA were subject 
and study day). A priori, the variables Cmax, AUC∞, AUC0-t, and 
AUCτ were log-transformed. Point estimates and 90% CIs for 
treatment differences on the log scale were e  xponentiated to 
obtain point estimates and 90% CIs for the day 9 to 1 ratios 
of geometric means for Cmax, AUC∞, and AUC0-t of saxagliptin Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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and 5-hydroxy saxagliptin, as well as for the day 9 to day 8 
ratios of geometric means for Cmax and AUCτ of diltiazem 
extended-release, on the original scale of measurement.
Ketoconazole study
The sample size for this study was not based on   statistical 
power considerations. However, data from 14 subjects 
would provide at least 99% CI that the point estimates for 
the day 9 to day 1 ratios of geometric means for Cmax and 
AUC of saxagliptin would be within 20% of the true ratio 
of population geometric means. Data from 14 subjects 
would also provide 80% and 81% CI, respectively, that 
the point estimates for the day 9 to day 8 ratios of geo-
metric means for Cmax and AUC of ketoconazole would 
be within 20% of the true ratio of population geometric 
means. To allow for dropouts, 16 subjects were to be 
enrolled.
ANOVA was performed on Cmax, AUC∞, and AUC0-t of 
saxagliptin and 5-hydroxy saxagliptin, and on Cmax and AUCτ 
of ketoconazole (factors in the ANOVA were subject and 
study day). A priori, the variables Cmax, AUC∞, AUC0-t, and 
AUCτ were log-transformed. Point estimates and 90% CIs 
for treatment differences on the log scale were exponentiated 
to obtain point estimates and 90% CIs for the day 9 to day 
1 ratios of geometric means for Cmax, AUC∞, and AUC0-t of 
saxagliptin and 5-hydroxy saxagliptin, and for the day 9 to 
day 8 ratios of geometric means for Cmax and AUCτ of keto-
conazole, on the original scale of measurement.
Results
subject demographics and disposition
In the simvastatin study, 24 men were randomized and 
administered the study drugs. One subject discontinued 
on day 9 due to an adverse event. In the diltiazem study, 
14 subjects were randomized and administered study drugs. 
Two subjects discontinued from the study, 1 on day 6 and 1 
on day 8, due to adverse events. In the ketoconazole study, 
16 subjects were randomized and administered study drugs. 
One subject discontinued from the study on day 8 due to an 
adverse event.
Pharmacokinetics
The pharmacokinetic parameters for saxagliptin, 5-hydroxy 
saxagliptin, simvastatin, diltiazem extended-release, 
and ketoconazole in their respective studies are listed in 
Tables 2a–c.
Mean plasma concentration-time profiles following 
administration of study drugs are provided for the simvastatin 
(Figure 2), diltiazem extended-release (Figure 3), and   
ketoconazole (Figure 4) studies.
simvastatin study
Simvastatin increased the Cmax of saxagliptin and 5-hydroxy 
saxagliptin by 21% and 8%, respectively, relative to 
  saxagliptin alone. Similarly, the AUCτ of saxagliptin and 
5-hydroxy s  axagliptin increased by 12% and 2%, respectively. 
Saxagliptin decreased the Cmax of simvastatin by 12%, while 
the Cmax of simvastatin acid was unchanged. Saxagliptin 
increased the AUCτ of simvastatin and simvastatin acid by 
4% and 16%, respectively, relative to simvastatin alone. 
Data from the s  ubject who discontinued were not used in 
the analysis.
Diltiazem extended-release study
Diltiazem extended-release increased the Cmax  of 
saxagliptin by 63% and decreased the Cmax of 5-hydroxy 
saxagliptin by 43% compared with those observed following 
oral   administration of saxagliptin 10 mg alone. Similarly, 
d  iltiazem extended-release increased the AUC∞ and AUC0-t 
of saxagliptin by 109% and 113%, respectively; however, 
those values were decreased for 5-hydroxy saxagliptin (AUC∞ 
by 34%; AUC0-t by 36%). Saxagliptin increased the Cmax 
and AUCτ of diltiazem extended-release by 16% and 10%, 
respectively. Data for the two discontinued subjects were 
excluded from this analysis.
Ketoconazole study
Ketoconazole increased the Cmax of saxagliptin by 62%, 
and decreased the Cmax of 5-hydroxy saxagliptin by 95%. 
Further, ketoconazole increased the AUC∞ and AUC0-t of 
saxagliptin by 145% and 148%, respectively; however, these 
values were decreased for 5-hydroxy saxagliptin (AUC∞ 
by 88%; AUC0-t by 91%) compared with saxagliptin alone. 
Saxagliptin decreased the Cmax and AUCτ of ketoconazole 
by 16% and 13%, respectively. Data from the discontinued 
subject were excluded from the summary statistics and 
statistical analysis of saxagliptin, 5-hydroxy saxagliptin, 
and ketoconazole.
Adverse events
There were no serious adverse events or deaths reported after 
coadministration of saxagliptin and simvastatin, diltiazem 
extended-release, or ketoconazole. Most of the reported 
adverse events were mild or moderate in intensity and 
generally resolved prior to discharge from each of the three 
studies.Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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simvastatin study
Eight adverse events were reported; six were considered   
possibly related to treatment. All adverse events were mild 
in intensity and all but three adverse events in two subjects 
resolved prior to study discharge (mild edema in an unspeci-
fied area, mild upper respiratory tract infection, and lower back 
pain). One subject was discontinued from the study (simvastatin 
40-mg group) due to a mild upper respiratory tract infection 
diagnosed on day 5, which was deemed possibly related to study 
drug by the investigator. The most common adverse event was 
headache, which occurred in two (8.3%) subjects.
Diltiazem extended-release study
Thirteen adverse events were reported; 12 of these occurred 
in subjects receiving diltiazem extended-release 360 mg 
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Figure 2 Mean (± standard deviation) plasma saxagliptin, 5-hydroxy saxagliptin, and 
simvastatin concentration-time profiles following oral administration of saxagliptin 
10 mg with or without simvastatin 40 mg, or simvastatin 40 mg with or without 
saxagliptin 10 mg.
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Figure 3 Mean (± standard deviation) plasma saxagliptin, 5-hydroxy saxagliptin, and 
diltiazem extended-release concentration-time profiles following oral administration   
of  saxagliptin  10  mg  with  and  without  diltiazem  extended-release  360  mg,  or 
diltiazem extended-release 360 mg with or without saxagliptin 10 mg.
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monotherapy. All adverse events were of mild or moder-
ate intensity. The most common adverse event was first-
degree atrioventricular block, occurring in six (42.9%) 
subjects treated with diltiazem extended-release 360 mg 
alone; two of these subjects discontinued the trial on day 5.   
In c  omparison, the adverse event of first-degree atrioven-
tricular block occurred in two (17%) subjects treated with 
saxagliptin 10 mg and diltiazem extended-release 360 mg, 
but in no subjects treated with saxagliptin 10 mg alone. All 
events of first-degree atrioventricular block resolved without 
treatment before study discharge.
Ketoconazole study
Fifty-four adverse events were reported; all were   considered 
mild in intensity. Approximately half (24) of all adverse events 
were considered possibly treatment-related; 19 adverse events 
were considered probably treatment-related.   Headache was 
the most frequently reported adverse event, occurring in 
10/16 (62.5%) subjects in the ketoconazole alone treat-
ment group. Lymphopenia was observed in 5/15 (33.3%) 
subjects in the saxagliptin + ketoconazole group; in four of 
the five subjects, lymphopenia was linked to pyrexia and/or 
chills. Subjects in the saxagliptin + ketoconazole group also 
reported chills and myalgia (4/15 [26.7%]) and pyrexia with 
nausea (3/15 [20.0%]). One subject was discontinued from 
the study due to an adverse event of increased transaminases, 
which was considered mild in intensity, beginning on day 
8 and lasting for 11 days following administration of keto-
conazole alone.
Discussion
The purpose of these studies was to profile the extent to 
which saxagliptin pharmacokinetics may be affected by 
coadministration of substrates and inhibitors of CYP3A4. 
Many medicines, including several 3-hydroxy-3 methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors 
(eg, lovastatin, simvastatin), antihypertensives (eg, diltiazem, 
nifedipine, verapamil), and antifungals (eg, ketoconazole) 
are metabolized by and/or inhibit the CYP3A4 metabolic 
pathway.3 These types of medicines are commonly   
coprescribed to treat comorbidities in patients with T2DM, 
and the potential for drug-drug interactions must be carefully 
considered when developing new medicines to treat T2DM, 
such as saxagliptin.4
The primary objectives of these three clinical   pharmacology 
studies were to evaluate the pharmacokinetic interactions 
between saxagliptin and a CYP3A4 substrate, simvastatin; 
a moderate inhibitor of CYP3A4, diltiazem extended-release; 
and a potent inhibitor of CYP3A4, ketoconazole. The major 
metabolic pathway for saxagliptin is through the formation 
of 5-hydroxy saxagliptin via CYP3A4/5 and this analysis 
of the pharmacokinetics of both saxagliptin and 5-hydroxy 
saxagliptin is expected to provide a sensitive measure of the 
effect of concomitantly administered medicines on CYP3A4 
a  ctivity.1 Furthermore, the effect of saxagliptin on these arche-
typal CYP3A4 substrates and inhibitors was also evaluated. 
The results from the simvastatin, diltiazem extended-release, 
and ketoconazole studies can also be reasonably applied to 
other medications that share, or moderately or potently inhibit 
CYP3A4. Although not all moderate/potent inhibitors of 
CYP3A4/3A5 activity have been studied for drug interaction 
with saxagliptin, it is reasonable to assume that the results 
from the simvastatin, diltiazem, and ketoconazole drug-drug Clinical Pharmacology: Advances and Applications 2011:2
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Figure 4 Mean (± standard deviation) plasma saxagliptin, 5-hydroxy saxagliptin, and 
ketoconazole concentration-time profiles following oral administration of saxagliptin 
100 mg with and without ketoconazole 200 mg every 12 hours, or ketoconazole 
200 mg every 12 hours with and without saxagliptin 100 mg.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
22
Boulton et al
interaction studies would be generally reproduced when other 
substrates or moderate or potent inhibitors of CYP3A4/3A5 
enzymes are coadministered with saxagliptin.
When saxagliptin was coadministered with simvastatin, 
a substrate that is considered to be sensitive to changes 
in CYP3A4 activity, there was no meaningful impact of 
saxagliptin on simvastatin pharmacokinetic parameters. 
Because the study was conducted under steady-state condi-
tions, the data support a conclusion that saxagliptin neither 
induces nor inhibits CYP3A4 activity. Simvastatin is also a 
substrate of P-glycoprotein as well as OATP1B1.5 The lack of 
a clinically meaningful change in simvastatin and simvastatin 
acid pharmacokinetics also indicates that saxagliptin does not 
modulate the activity of these transporters. While there was a 
small increase in saxagliptin exposure when saxagliptin was 
coadministered with simvastatin (21% and 12% increases 
in saxagliptin Cmax and AUCτ, respectively), there was no 
clear corresponding change in the exposure to 5-hydroxy 
saxagliptin, suggesting that alteration of CYP3A4 metabo-
lism may not be the mechanism for the small increase in 
parent exposure.
Consistent with the inhibition of CYP3A4 by diltiazem and 
ketoconazole in subjects receiving saxagliptin and these inhibi-
tors, increases in the systemic exposure and t½ of s  axagliptin 
were observed, accompanied by decreases in the exposure to 
5-hydroxy saxagliptin. As expected, these effects were more 
pronounced for ketoconazole (a potent CYP3A4 inhibitor) 
where mean saxagliptin t½ and AUC∞ values were increased 
by 1.1 hours and 145%, respectively, compared with diltiazem 
extended-release (a moderate CYP3A4 inhibitor), where mean 
saxagliptin t½ and AUC∞ values were increased by 0.92 hours 
and 109%, respectively. The effect of ketoconazole and 
  diltiazem extended-release on saxagliptin Cmax was similar 
(62% and 63% increased, r  espectively). Both diltiazem and 
ketoconazole are also inhibitors of P-glycoprotein.6,7 The extent 
to which saxagliptin undergoes a P-glycoprotein-mediated 
efflux in the intestinal wall is not known, but it is likely to 
be small because saxagliptin is considered to be a weak sub-
strate of P-glycoprotein. The similar effects of diltiazem and 
ketoconazole on saxagliptin Cmax indicate that their inhibition 
of the first-pass clearance of saxagliptin, including intestinal 
wall inhibition of P-glycoprotein, may be similar and that the 
differences observed in AUC∞ may be mainly due to their dif-
ferential effect on the systemic clearance of saxagliptin (keto-
conazole being the relatively stronger inhibitor of CYP3A4). 
However, s  axagliptin also undergoes active renal excretion 
(approximately 230 mL/min) and this route enables relatively 
efficient clearance despite the suppression of metabolic clear-
ance through CYP3A4.
The Phase III program for saxagliptin has studied doses of 
up to 10 mg once daily for more than two years. Saxagliptin 
10 mg once daily is considered to have a favorable safety 
and tolerability profile.8 The magnitude of the increase in 
  saxagliptin Cmax and AUC∞ observed with coadministration of 
diltiazem extended-release and ketoconazole is such that if the 
usual saxagliptin dose of 5 mg is administered, the systemic 
exposures will be within or near the long-term exposures 
observed in the Phase III program.9 Exposures to 5-hydroxy 
saxagliptin are substantially reduced with CYP3A4 inhibition. 
Furthermore, the increases in saxagliptin t½ values observed 
with coadministration CYP3A4 inhibitors (up to 1.1. hours) Clinical Pharmacology: Advances and Applications 2011:2 submit your manuscript | www.dovepress.com
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indicate that saxagliptin will not accumulate following once-
daily dosing under these circumstances, and the single-dose 
data generated in the studies presented here are considered 
reflective of the changes expected at steady state.
Small changes in diltiazem extended-release and keto-
conazole exposures were observed when saxagliptin was 
coadministered. The magnitude of these changes is such 
that they are unlikely to be clinically meaningful and these 
findings may be due to chance, attributable to the relatively 
small sample sizes. Importantly, diltiazem and ketoconazole 
are not generally considered sensitive probes of CYP3A4 
activity because they inhibit their own metabolism. Thus, 
these results are not indicative of the effect of saxagliptin 
on CYP3A4 activity.
In conclusion, knowledge of the pharmacokinetics 
of concomitantly administered medications and their 
  interactive mechanisms for metabolism may help to reduce 
or avoid adverse reactions in patients with T2DM without 
compromising therapeutic benefits.10,11   Saxagliptin, when 
coadministered with simvastatin,   diltiazem extended-  release, 
or ketoconazole, was safe and generally well   tolerated in 
healthy subjects. Saxagliptin, a CYP3A4   substrate, does 
not appear to affect the activity of CYP3A4, as determined 
by a lack of effect on simvastatin pharmacokinetics. Up to 
145% increases in saxagliptin exposure are observed when 
saxagliptin is administered with diltiazem or ketoconazole, 
moderate and potent CYP3A4 inhibitors, respectively. 
In patients with T2DM administered the usual daily dose 
of 5 mg, systemic exposures of s  axagliptin resulting from 
coadministration of moderate or strong CYP3A4 inhibi-
tions are expected to result in exposures that are considered 
generally safe and well tolerated in long-term clinical stud-
ies. The dose of saxagliptin does not need to be adjusted 
when coadministered with a substrate or moderate inhibi-
tor of CYP3A4. A limitation to the lowest clinical dose of 
saxagliptin (2.5 mg) is proposed when it is coadministered 
with a potent CYP3A4 inhibitor like ketoconazole.
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Supplementary Table 1 Comprehensive inclusion and exclusion criteria for saxagliptin coadministered with simvastatin (CV181033), 
diltiazem Xr (CV181053), or ketoconazole (CV181005) studies
Inclusion criteria Signed written informed consent
Target population
•   Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical 
examination, electrocardiograms, and clinical laboratory determinations
•   Body mass index 18–35 kg/m2 (CV181033), 18–32 kg/m2 (CV181053), and 18–30 kg/m2 (CV181005), inclusive
Age and gender
•   Men and women who were not of childbearing potential (ie, who were postmenopausal or surgically sterile), 
18–45 years of age
•   Women were considered surgically sterile only if they had undergone a hysterectomy, bilateral tubal ligation, 
or bilateral oophorectomy
•   Women were considered postmenopausal only if they had amenorrhea for $12 consecutive months, or 
for women on hormone replacement therapy, if they had a documented serum follicle-stimulating hormone 
level .35 miU/mL
Exclusion criteria Gender and reproductive status
•   Women of childbearing potential included any female who had experienced menarche and who had not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) 
or was not postmenopausal as defined in inclusion criteria. Even women who were using oral, implanted, 
or injectable contraceptive hormones, or mechanical products, such as an intrauterine device or barrier 
methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence, or whose 
partner was sterile (eg, vasectomy) were considered to be of childbearing potential
• Women who were pregnant or breastfeeding
•   Women with a positive pregnancy test on enrollment or prior to study drug administration
•   sexually active fertile men not using effective birth control if their partners were women of childbearing 
potential (CV181053 only)
Medical history and concurrent diseases
• Any significant acute or chronic medical illness
• Current or recent (within three months) gastrointestinal disease
• Any major surgery within four weeks of enrollment
•   Any gastrointestinal surgery that could have impacted upon the absorption of study drug
• Any history of rhabdomyolysis (CV181033)
•   Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within  
four weeks of enrollment
• Blood transfusion within four weeks of enrollment
• inability to tolerate oral medication
• inability to be venipunctured and/or tolerate venous access
•   Recent (within six months) drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug  
and Alcohol Abuse
•   Any other sound medical, psychiatric, and/or social reason as determined by the investigator
• history of low blood pressure or orthostatic hypotension (CV181053)
•   Any current or previous history of nicotine use for at least one year prior to dosing (CV181053)
Physical and laboratory test findings
•   Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital 
signs, electrocardiogram, or clinical laboratory determinations. A clinically significant laboratory abnormality 
is defined as a value .1.25 × upper limit of normal and , 0.85 × lower limit of normal when low values are 
clinically significant, eg, calcium
•   Positive urine screen for drugs of abuse either at screening or before dosing
• Positive blood screen for hepatitis C antibody
•   History or evidence on screening of clinically significant arrhythmias, including but not limited to 
atrioventricular block, sick sinus syndrome, Wolff-Parkinson-White syndrome, and sinus bradycardia  
(heart rate ,55 beats per minute) (CV181053)
•   heart rate ,55 beats per minute based on screening and day 1 predose evaluations (CV181053)
•   Blood pressure ,100/60 mmhg based on screening and day 1 predose evaluations (CV181053)
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Supplementary Table 1 (Continued)
Allergies and adverse drug reactions
•   history of allergy to DPP-4 inhibitors, hMg-CoA reductase inhibitors (CV181033 only), diltiazem extended-
release (CV181053 only), ketoconazole (CV181005 only), or related compounds
• History of any significant drug allergy
Prohibited therapies and/or medications
• Prior exposure to saxagliptin
•   exposure to any investigational drug or placebo within four weeks of enrollment
•   Use of any prescription drugs or over-the-counter acid controllers within four weeks prior to enrollment
•   Use of any other drugs, including over-the-counter medications and herbal preparations, within one week 
prior to enrollment
•   Use of an oral, injectable, or implantable hormonal contraceptive agent within three months of enrollment
Other exclusion criteria
•   Prisoners or subjects who were compulsorily detained (involuntarily incarcerated) for treatment of either a 
psychiatric or physical (eg, infectious disease) illness
•   subjects who smoked (CV181005) or who had smoked in the 30 days prior to screening (CV181033)
Abbreviations: DsM-iV, Diagnostic and statistical Manual of Mental Disorders (4th edition); DPP-4, dipeptidyl peptidase-4; hMg-CoA, 3-hydroxy-3 methylglutaryl 
coenzyme A.
Supplementary Table 2 Pharmacokinetic blood sample schedule in the ketoconazole study
Study day Saxagliptin, 5-hydroxy saxagliptin  
Pharmacokinetic sampling time (hours)
Ketoconazole  
Pharmacokinetic sampling time (hours)a
1 0 (predose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6,  
8, 10, 12, 18
2 24, 36
3 48
6 0 (predose)
7 0 (predose)
8 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,  
3, 4, 5, 6, 7, 8, 10, 12
9 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7,  
8, 10, 12, 16, 20
0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2,  
2.5, 3, 4, 5, 6, 7, 8, 10, 12
10 24, 36
11 48, 60
12 72
Note: arelative to morning dose of ketoconazole.